Recent data from July 2026 highlights a significant connection between Hepatitis B virus infection and erectile dysfunction (ED). Approximately 76.4% of infected men experience some form of erectile issues, with 60.3% suffering from severe cases.
When the Liver Impacts Libido
The underlying causes of these erectile issues are largely hormonal imbalances. According to Dr. Mohit Khera from Baylor College, patients with liver disease often exhibit high levels of sex hormone-binding globulin (SHBG) alongside decreased albumin levels. The outcome is reduced free testosterone in the bloodstream. Given that testosterone is crucial for libido and erectile function, a deficiency directly translates to clinical symptoms.
Moreover, psychological factors play a substantial role. Chronic fatigue and stress associated with the disease’s progression and its long-term treatment exacerbate the problem. Alcohol consumption further aggravates liver damage, indirectly impairing sexual functionality.
New Therapy: Antisense Medication Shows Promise
Amidst progressing knowledge about co-morbidities, treatment options are advancing as well. In May 2026, GSK released data on Bepirovirsen, an antisense oligonucleotide. A Phase-III study published in the New England Journal of Medicine achieved functional cure rates of up to 26%, marking a significant milestone for chronic cases.
Diagnostic improvements are also noteworthy. A study published in July 2026 in Hepatobiliary Communications from the First Hospital of Lanzhou University indicates that CT-based measurements of fat and muscle changes can accurately predict severe complications arising from Hepatitis B-related cirrhosis. While visceral fat degeneration signals risks in compensated cirrhosis, persistent muscle loss indicates complications in decompensated cases.
AI Aids Early Detection
Technological advancements are becoming increasingly essential in the healthcare sphere. In July 2026, ALZAI Health Corp secured an exclusive worldwide license for an AI-based technology aimed at identifying risks for liver diseases. This data-driven solution promises to enhance the early detection of cirrhosis risks.
A Global Fight Against Hepatitis B
Internationally, nations are amplifying their efforts to combat Hepatitis B. In China, for instance, around 75 million individuals are chronically infected with HBV. The country’s action plan for 2025 to 2030 aims for the near elimination of the disease, with vaccination rates in children already exceeding 95%.
The preservation of musculature is pivotal in maintaining fitness and resilience amidst long-term health challenges. For tailored insights, an expert guide is available that details how to achieve maximum results with minimal effort in home training.
Progress in Pakistan
Pakistan is also witnessing advancements. A recent B2B agreement with China aims to expedite access to modern therapies for the Hepatitis Delta co-infection. Over a million individuals in Pakistan are affected by Hepatitis Delta, prompting the DRAP regulatory authority to prioritize corresponding medications.
Experts continue to underscore the importance of vaccination and annual screenings to prevent long-term consequences, such as liver cell carcinoma or recently researched sexual dysfunction issues.
Disclaimer: No investment advice, no buy or sell recommendations. Market information is subject to change; investing can lead to significant losses. Our articles are generated or reviewed automatically with AI assistance.
